Pages that link to "Q38857820"
Jump to navigation
Jump to search
The following pages link to Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review (Q38857820):
Displaying 10 items.
- Biologic therapies and bone loss in rheumatoid arthritis. (Q30243911) (← links)
- The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting (Q39029106) (← links)
- Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis. (Q39367839) (← links)
- Personalized medicine in rheumatology: the paradigm of serum autoantibodies (Q39432157) (← links)
- Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis. (Q46671185) (← links)
- Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection (Q60300744) (← links)
- Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry (Q64247865) (← links)
- [Management of rheumatoid arthritis] (Q88338785) (← links)
- Experience With the Use of Rituximab for the Treatment of Rheumatoid Arthritis in a Tertiary Hospital in Spain: RITAR Study (Q89997443) (← links)
- Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies (Q96298839) (← links)